Migraine Research in 2025: Breakthroughs and What's Next
For most of the twentieth century, migraine prevention ran on borrowed drugs. Blood pressure medications, antidepressants, anti-seizure drugs — all discovered to help migraine by accident, none designed for it. The triptans, arriving in the 1990s, were the first real exception: purpose-built for migraine from the serotonin-receptor work of the preceding decade. But they treated attacks already underway, and on the prevention side the borrowed-drug era continued.
That changed over the past decade, and by 2025 the shape of the field looked genuinely different — the first preventives designed specifically for migraine, a second acute drug class for people triptans never suited, and a deeper pipeline behind both than migraine research has ever had. This is a look at what changed, what it means in practice, and where the work is heading next.